• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

将细胞疗法应用于B细胞急性淋巴细胞白血病二线治疗的前沿。

Moving cellular therapies to the front line for Ph B cell acute lymphoblastic leukemia.

作者信息

Feng Yanzhi, Leveille Etienne, Park Jae H, Müschen Markus

机构信息

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.

Cellular Therapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Cell Rep Med. 2025 Jul 15;6(7):102184. doi: 10.1016/j.xcrm.2025.102184.

DOI:10.1016/j.xcrm.2025.102184
PMID:40669449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281393/
Abstract

Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability..

摘要

由于化疗存在局限性，无化疗方案作为B细胞急性淋巴细胞白血病（B-ALL）的一线治疗方法越来越受到关注。张及其同事开展了首个将嵌合抗原受体T细胞（CAR-T）纳入Ph B-ALL一线治疗的试验，显示出显著的疗效和耐受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff72/12281393/8a42f0aa3e13/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff72/12281393/8a42f0aa3e13/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff72/12281393/8a42f0aa3e13/gr1.jpg

相似文献

1
Moving cellular therapies to the front line for Ph B cell acute lymphoblastic leukemia.将细胞疗法应用于B细胞急性淋巴细胞白血病二线治疗的前沿。
Cell Rep Med. 2025 Jul 15;6(7):102184. doi: 10.1016/j.xcrm.2025.102184.
2
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.达沙替尼与嵌合抗原受体T细胞疗法治疗新诊断的费城染色体阳性急性淋巴细胞白血病：一项非随机临床试验
JAMA Oncol. 2025 Apr 17. doi: 10.1001/jamaoncol.2025.0674.
3
Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia.嵌合抗原受体（CAR）T细胞和单采产物的免疫表型可预测B细胞急性淋巴细胞白血病CD22 CAR T细胞试验中的反应。
Mol Ther. 2025 Mar 13. doi: 10.1016/j.ymthe.2025.03.019.
4
Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee.嵌合抗原受体T细胞（CAR-T）疗法时代小儿急性淋巴细胞白血病的移植后复发。西班牙血液移植与细胞治疗协作组（GETH-TC）儿科委员会的多中心分析
Cytotherapy. 2025 Apr;27(4):438-445. doi: 10.1016/j.jcyt.2024.11.016. Epub 2024 Dec 2.
5
The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025.2025年移植在费城染色体阳性B细胞急性淋巴细胞白血病中的作用
Curr Oncol Rep. 2025 May 9. doi: 10.1007/s11912-025-01683-1.
6
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.针对CD19导向免疫治疗后复发的B细胞急性淋巴细胞白血病儿童和成人的CD22靶向嵌合抗原受体修饰T细胞
J Immunother Cancer. 2025 Apr 17;13(4):e011549. doi: 10.1136/jitc-2025-011549.
7
CAR T-cells for acute leukemias in children: current status, challenges, and future directions.用于儿童急性白血病的嵌合抗原受体T细胞：现状、挑战及未来方向
Cancer Metastasis Rev. 2025 Apr 23;44(2):47. doi: 10.1007/s10555-025-10261-7.
8
CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法联合造血干细胞移植可改善费城染色体阳性 B 细胞急性淋巴细胞白血病复发/难治患儿的生存。
J Pediatr Hematol Oncol. 2024 Jul 1;46(5):241-247. doi: 10.1097/MPH.0000000000002861. Epub 2024 Apr 23.
9
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.全血细胞毒性的发展：预测B细胞急性淋巴细胞白血病中CAR T细胞治疗后的血液毒性
Blood. 2025 Mar 13;145(11):1136-1148. doi: 10.1182/blood.2024025910.
10
Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemia.B淋巴细胞系急性淋巴细胞白血病的治疗中免疫疗法越来越多。
Med. 2025 Feb 14;6(2):100603. doi: 10.1016/j.medj.2025.100603.

本文引用的文献

1
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.IKAROS水平与B细胞恶性肿瘤的CD19和CD22靶向治疗中的抗原逃逸相关。
Nat Commun. 2025 Apr 23;16(1):3800. doi: 10.1038/s41467-025-58868-2.
2
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.针对CD19导向免疫治疗后复发的B细胞急性淋巴细胞白血病儿童和成人的CD22靶向嵌合抗原受体修饰T细胞
J Immunother Cancer. 2025 Apr 17;13(4):e011549. doi: 10.1136/jitc-2025-011549.
3
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
达沙替尼与嵌合抗原受体T细胞疗法治疗新诊断的费城染色体阳性急性淋巴细胞白血病：一项非随机临床试验
JAMA Oncol. 2025 Apr 17. doi: 10.1001/jamaoncol.2025.0674.
4
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.达沙替尼-blinatumomab 方案治疗成人费城阳性 ALL 的长期结果。
J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21.
5
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.序贯 CD19 和 CD22 嵌合抗原受体 T 细胞治疗儿童难治或复发 B 细胞急性淋巴细胞白血病：单臂、2 期研究。
Lancet Oncol. 2023 Nov;24(11):1229-1241. doi: 10.1016/S1470-2045(23)00436-9. Epub 2023 Oct 17.
6
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.帕纳替尼和blinatumomab 治疗费城染色体阳性急性淋巴细胞白血病：美国单中心、单臂、2 期临床试验。
Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
7
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.达沙替尼/泼尼松诱导后，费城染色体阳性急性淋巴细胞白血病采用blinatumomab/达沙替尼治疗。
Blood Adv. 2023 Apr 11;7(7):1279-1285. doi: 10.1182/bloodadvances.2022008216.
8
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.达沙替尼联合博纳吐单抗治疗成人费城染色体阳性急性淋巴细胞白血病。
N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.
9
Pharmacologic control of CAR-T cell function using dasatinib.使用达沙替尼对 CAR-T 细胞功能进行药物控制。
Blood Adv. 2019 Mar 12;3(5):711-717. doi: 10.1182/bloodadvances.2018028720.
10
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.BCR-ABL1 淋巴细胞白血病的特征是 Ikaros 缺失。
Nature. 2008 May 1;453(7191):110-4. doi: 10.1038/nature06866. Epub 2008 Apr 13.